Nomura Holdings Inc. Has $1.81 Million Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Nomura Holdings Inc. lifted its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 187.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 52,607 shares of the company’s stock after buying an additional 34,308 shares during the period. Nomura Holdings Inc.’s holdings in Harmony Biosciences were worth $1,810,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of HRMY. KBC Group NV boosted its stake in shares of Harmony Biosciences by 79.9% during the 4th quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after buying an additional 819 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Harmony Biosciences by 28.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company’s stock worth $80,000 after buying an additional 519 shares during the last quarter. Summit Investment Advisors Inc. boosted its stake in shares of Harmony Biosciences by 34.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,987 shares of the company’s stock worth $137,000 after buying an additional 1,029 shares during the last quarter. Avanza Fonder AB acquired a new position in shares of Harmony Biosciences during the 4th quarter worth about $145,000. Finally, CIBC Private Wealth Group LLC boosted its stake in shares of Harmony Biosciences by 66.4% during the 4th quarter. CIBC Private Wealth Group LLC now owns 4,214 shares of the company’s stock worth $146,000 after buying an additional 1,681 shares during the last quarter. 86.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on HRMY shares. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Needham & Company LLC reiterated a “buy” rating and issued a $49.00 target price on shares of Harmony Biosciences in a research note on Tuesday, May 6th. Mizuho raised their target price on shares of Harmony Biosciences from $44.00 to $48.00 and gave the company an “outperform” rating in a research note on Thursday. Deutsche Bank Aktiengesellschaft started coverage on shares of Harmony Biosciences in a research note on Tuesday, February 11th. They issued a “buy” rating and a $55.00 target price for the company. Finally, UBS Group cut their target price on shares of Harmony Biosciences from $55.00 to $48.00 and set a “buy” rating for the company in a research note on Monday, April 28th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $52.78.

Harmony Biosciences Stock Up 2.5%

Harmony Biosciences stock opened at $35.07 on Friday. The stock has a market cap of $2.01 billion, a P/E ratio of 16.62, a P/E/G ratio of 0.47 and a beta of 0.82. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. Harmony Biosciences Holdings, Inc. has a twelve month low of $26.47 and a twelve month high of $41.61. The company’s 50-day moving average price is $31.45 and its two-hundred day moving average price is $33.96.

Harmony Biosciences (NASDAQ:HRMY) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.19. The firm had revenue of $184.73 million for the quarter, compared to analysts’ expectations of $184.26 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business’s revenue was up 19.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.67 EPS. As a group, analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.